Results
DISEASE CHARACTERISTIC
Participant baseline demographics and disease characteristics, and participant disposition in Protocol T have previously been described [The mean time in range for the three anti-VEGF agents according to three BCVA letter score thresholds, and unadjusted for baseline BCVA, are shown in Fig. 